2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

637. Myelodysplastic Syndromes: Clinical and Epidemiological

Program: Oral Abstract Session
Monday, December 14, 2026
10:30 a.m. - 12:00 p.m.
MCCNO - Great Hall AD
Technology and Procedures, Molecular Testing, Omics Technologies, Biological Processes, CHIP, Genomics, Hematopoiesis, Molecular Biology, Diseases, Bone Marrow Failure Syndromes, Inherited Marrow Failure Syndromes, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Research, AML, Translational Research, MDS, MPN, CMML, Clinical Research, Clinical Trials, Study Population, Human, Animal Model
PAPER

809 Elritercept achieves high and durable response rates in lower-risk myelodysplastic syndrome (MDS), including patients with non-ring sideroblast (RS) disease and high transfusion burden (HTB), with quality-of-life (QoL) improvement

David Valcarcel, MD, PhD, Lynette C.Y. Chee, PhD, MBBS, FRACP, FRCPA2, Montserrat Arnan Sangerman Sr, PhD3, Alejandro Arbelaez4, Anish Puliyayil5, Teresa Bernal del Castillo6, David M. Ross, MBBS, PhD7, Devendra Hiwase I, Consultant Haematologist8, Maria Diez-Campelo, MD, PhD9, John Kwan, Westmead Hospital10, Thomas Cluzeau, MD, PhD11, Joel Wight12, Hannah Rose13, Camden Bay14, Meng Yang, PhD15, Leopold Sellner, MD, PhD16, Kaveri Suryanarayan, MD17, Shuh Ying Tan, MBBS, FRACP, FRCPA18
1 Vall d’Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain
2 The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
3 Institut Català d’Oncologia, IDIBELL, Hospitalet de Llobregat, Barcelona, Spain
4 Tweed Valley Hospital, Cancer Care Services, Cudgen, New South Wales, Australia
5 Border Medical Oncology and Haematology, Albury, New South Wales, Australia
6 Hospital Universitario Central de Asturias, ISPA, IUOPA, Oviedo, Spain
7 Flinders Medical Centre, Adelaide, South Australia, Australia, Royal Adelaide Hospital, Adelaide, South Australia, Australia
8 Royal Adelaide Hospital, Adelaide, South Australia, Australia
9 Complejo Asistencial Universitario de Salamanca, CAUSA, IBSAL, Salamanca, Spain
10 Westmead Hospital, Sydney, New South Wales, Australia
11 CHU de Nice, Nice, France
12 Townsville University Hospital, Townsville, Queensland, Australia
13 Barwon Health, Geelong, VIC, Australia and Deakin University, Geelong, Victoria, Australia
14 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
15 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
16 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
17 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
18 St. Vincent’s Hospital, Melbourne, Victoria, Australia

Background: Management of anemia in patients (pts) with non-RS disease and HTB remains a substantial unmet need in lower-risk MDS (LR-MDS) despite availability of current therapies. Elritercept is an investigational, potent, modified activin receptor type IIA/IgG1 fusion protein that binds and inhibits select TGF-β superfamily ligands (activins A/B, GDF 8/11), which is being evaluated for anemia in LR-MDS and myelofibrosis. We report updated results from the ongoing phase 2 trial in LR-MDS (NCT04419649), focusing on durability of responses in pts with non-RS disease and HTB, as well as pt-reported outcomes, including fatigue and anemia-related symptoms.

Methods: Transfusion-dependent pts with International Prognostic Scoring System-Revised Very Low-, Low-, or Intermediate-risk MDS were evaluated for transfusion independence (TI) and hematologic improvement-erythroid (HI-E) per Modified International Working Group 2006 criteria (mean increase in hemoglobin ≥1.5 g/dL in non-transfusion-dependent pts and low transfusion burden pts, or reduction in transfusion of ≥4 red blood cell [RBC] units over 8 weeks in HTB pts on treatment compared with the 8-week pretreatment period). TI rates (≥8 weeks and ≥24 weeks) were analyzed over the first 24 and 48 weeks of treatment, respectively, in pts who received ≥2 RBC units in the 8 weeks before treatment and completed ≥8 weeks (or ≥24 weeks) of transfusion assessments. Pts included in the HI-E analysis were defined similarly, except not requiring receipt of ≥2 RBC units 8 weeks before treatment. TI durability and time to first TI were assessed using Kaplan–Meier estimation. QoL outcomes were assessed by Functional Assessment of Cancer Therapy-Anemia (FACT-An) including FACT-General (FACT-G), the anemia subscale (AnS), and FACIT-Fatigue (13 items of AnS). 

Results: As of April 3, 2026, 97 pts were treated with elritercept at the recommended Part 2 dose (3.75 mg/kg); 77 were evaluable for analysis of TI; median exposure was 16.8 months. In the overall population, 39.0% of pts achieved TI ≥8 weeks within the first 24 weeks of treatment (this range used throughout for TI ≥8 weeks), and 31.8% achieved TI ≥24 weeks within the first 48 weeks (this range used throughout for TI ≥24 weeks). Among pts who achieved TI ≥8 weeks, 59.1% maintained TI at 48 weeks. Median duration of TI was 110.9 weeks (from the start of the longest qualifying TI interval to RBC transfusion or censoring), and the median time from first elritercept dose to the start of the first qualifying TI interval was 0.3 weeks. In subgroup analyses, TI ≥8 weeks was achieved by 28.0% of pts with non-RS disease, 46.0% with RS disease, and 29.3% with HTB. Corresponding rates of TI ≥24 weeks were 29.4%, 34.0%, and 18.0%, respectively, with 57.1% (non-RS), 59.7% (RS), and 51.3% (HTB) of those who achieved TI ≥8 weeks maintaining TI at 48 weeks. Among pts who achieved TI ≥8 weeks, median duration of TI was not reached in non-RS pts, 110.9 weeks in RS, and 134.1 weeks in HTB pts, with a median time from first elritercept dose to the start of the first qualifying TI interval of 0.3 weeks for all three subgroups. Among pts with baseline serum erythropoietin (EPO) levels <500 U/L, TI ≥8 weeks was achieved by 54.0% of pts overall, with 40.4% achieving TI ≥24 weeks. Within this EPO <500 U/L subgroup, rates of TI ≥8 weeks were 63.6% (non-RS), 52.6% (RS), and 41.7% (HTB), with responses of TI ≥24 weeks observed in 50.0%, 38.9%, and 23.5%, respectively. HI-E response within the first 24 weeks of follow-up was achieved in 52.6% (50/95) of pts. QoL outcomes were evaluated in TI-evaluable pts with available baseline and Week 24 data (n=51). In the overall population, improvements were observed in FACT-An, including fatigue (FACIT-Fatigue) and anemia-related symptoms, with greater improvements observed in pts achieving TI ≥24 weeks compared with non-responders. Subgroup analyses demonstrated QoL improvements, including reductions in fatigue in pts with non-RS disease, RS disease, and HTB.

Summary: Elritercept induces high and durable response rates in LR-MDS, including in pts with non-RS disease and HTB, populations with significant unmet need. Durable TI is accompanied by improvements in fatigue, anemia-related symptoms, and overall QoL, underscoring the clinical benefit of elritercept. Collectively, these findings support its continued evaluation in pts with LR-MDS in the ongoing phase 3 RENEW (NCT06499285) and ELRiSE-MDS (NCT07422480) trials.

David Valcarcel, MD, PhD: Amgen - Honoraria; Janssen - Honoraria; Pfizer - Honoraria; Jazz Pharmaceuticals - Honoraria; Gebro - Honoraria; Takeda - Honoraria; Johnson & Johnson - Honoraria; Astellas - Honoraria; Agios - Honoraria; Novartis - Honoraria; Merck Sharp & Dohme - Honoraria; Servier - Honoraria; Kite/Gilead - Honoraria; Sanofi - Honoraria; Bristol Myers Squibb/Celgene - Honoraria; GlaxoSmithKline - Honoraria; Grifols - Honoraria; Sobi - Honoraria; Agios - Research Funding; Bristol Myers Squibb/Celgene - Research Funding; Gebro - Consultancy (Includes expert testimony); Grifols - Consultancy (Includes expert testimony); Kite/Gilead - Consultancy (Includes expert testimony); Astellas - Consultancy (Includes expert testimony); Merck Sharp & Dohme - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Amgen - Consultancy (Includes expert testimony); GlaxoSmithKline - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Jazz Pharmaceuticals - Consultancy (Includes expert testimony); Servier - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Syros - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony)